Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives Consensus Rating of “Hold” from Brokerages

Cardiff Oncology, Inc. (NASDAQ:CRDF) has been given a consensus rating of “Hold” by the seven research firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $9.80.

CRDF has been the subject of a number of research reports. HC Wainwright cut shares of Cardiff Oncology from a “buy” rating to a “neutral” rating in a research note on Monday, June 1st. Wall Street Zen downgraded shares of Cardiff Oncology from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. TD Cowen lowered shares of Cardiff Oncology from a “buy” rating to a “hold” rating in a research report on Monday, June 1st. Craig Hallum downgraded Cardiff Oncology from a “buy” rating to a “hold” rating and set a $2.00 price target on the stock. in a research report on Wednesday, June 3rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cardiff Oncology in a research note on Monday, May 18th.

Insider Buying and Selling

In other news, CEO Mani Mohindru bought 24,703 shares of the company’s stock in a transaction that occurred on Thursday, June 18th. The stock was bought at an average price of $1.21 per share, for a total transaction of $29,890.63. Following the transaction, the chief executive officer directly owned 24,703 shares of the company’s stock, valued at $29,890.63. This represents a ? increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Gary W. Pace bought 30,000 shares of the business’s stock in a transaction on Thursday, June 18th. The stock was purchased at an average cost of $1.22 per share, with a total value of $36,600.00. Following the purchase, the director owned 1,356,376 shares of the company’s stock, valued at $1,654,778.72. This represents a 2.26% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders own 8.50% of the company’s stock.

Hedge Funds Weigh In On Cardiff Oncology

A number of large investors have recently added to or reduced their stakes in CRDF. Franklin Resources Inc. bought a new stake in Cardiff Oncology in the fourth quarter worth $3,388,000. Laurion Capital Management LP boosted its position in Cardiff Oncology by 37.2% during the third quarter. Laurion Capital Management LP now owns 2,465,872 shares of the company’s stock valued at $5,080,000 after buying an additional 668,590 shares during the period. Acorn Capital Advisors LLC grew its stake in shares of Cardiff Oncology by 39.3% during the third quarter. Acorn Capital Advisors LLC now owns 1,962,084 shares of the company’s stock valued at $4,042,000 after buying an additional 553,317 shares during the last quarter. Millennium Management LLC grew its stake in shares of Cardiff Oncology by 441.5% during the fourth quarter. Millennium Management LLC now owns 194,420 shares of the company’s stock valued at $546,000 after buying an additional 158,519 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Cardiff Oncology by 7.5% in the second quarter. Geode Capital Management LLC now owns 1,498,838 shares of the company’s stock worth $4,723,000 after buying an additional 104,409 shares during the period. Hedge funds and other institutional investors own 16.29% of the company’s stock.

Cardiff Oncology Price Performance

NASDAQ CRDF remained flat at $1.27 during trading on Friday. The company’s stock had a trading volume of 1,320,434 shares, compared to its average volume of 1,407,909. The stock has a 50 day moving average of $1.54 and a two-hundred day moving average of $1.90. Cardiff Oncology has a fifty-two week low of $1.16 and a fifty-two week high of $4.55. The company has a market capitalization of $86.83 million, a PE ratio of -1.90 and a beta of 1.44.

Cardiff Oncology (NASDAQ:CRDF) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.05). The business had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.09 million. Cardiff Oncology had a negative return on equity of 95.51% and a negative net margin of 8,527.43%. As a group, equities analysts forecast that Cardiff Oncology will post -0.66 earnings per share for the current year.

About Cardiff Oncology

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.